AffyImmune Therapeutics Appoints Deyaa Adib, MD as Chief Medical Officer: prnewswire.com/news-releases…
69
AffyImmune Appoints Drs. Rick Rutter and Jorge Nieva to Board of Directors
The addition of these leaders in clinical development and manufacturing strengthens AffyImmune’s commitment to advancing its AIC100 program in #thyroidcancer and #NSCLC.
businesswire.com/news/home/2…
Our CEO Daniel Janse is speaking on the Funding Biotech Innovation and Scaling up panel at @LSXLeaders #LSXWorldCongress
1
60
.@CancerNetwrk covers our recent RMAT designation for our CAR T therapy in #thyroidcancer.
cancernetwork.com/view/novel…
Pharmaceutical Business Review covers our recent RMAT designation in #thyroid cancer:
pharmaceutical-business-revi…
AffyImmune Therapeutics retweeted
Announced Today: @affyimmune Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AIC100 in Recurrent Anaplastic Thyroid Cancer
More: businesswire.com/news/home/2…
#lifesciences #biotech #thyroidcancer #FDA
AffyImmune Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AIC100 in Recurrent Anaplastic #Thyroid Cancer
Read the release:
businesswire.com/news/home/2…
38
AffyImmune Therapeutics retweeted
Replying to @affyimmune
@affyimmune Appoints Dr. Daniel Janse as Chief Executive Officer
readmagazine.com/industries/…
#Readmagazine #news #industries #Artificialintelligence #biotechnology #affyimmune #CARTcelltherapies
We’re excited to announce the appointment of Dr. Daniel Janse as President & CEO. Dr. Janse brings 20 years of expertise and an extensive background in #biopharma research and development, operations, and leadership.
Read the release:
businesswire.com/news/home/2…
46
Thanks @BioPharmReport for speaking with our CEO @mattbritz at #ASCO24 for this Q&A:
biopharma-reporter.com/Artic…
55
AffyImmune Therapeutics retweeted
ASCO 2024: Anticipation mounts for the latest advancements in cancer treatment.
Key companies, @AstraZeneca @DaiichiSankyoUS @Merck @affyimmune @Genmab, and others are prepared to unveil highlights in Head and Neck Cancer.
For More: tinyurl.com/y42rabta
#ASCO2024
AffyImmune Therapeutics retweeted
AffyImmune’s CAR-T sees first-ever complete response in solid tumour $AFFY #ASCO24 firstwordpharma.com/story/58…
AffyImmune Therapeutics retweeted
. @AffyImmune has recorded what it says is the first complete response in a patient with a solid tumour treated with CAR-T therapy at #ASCO24. #thyroidcancer
pharmaphorum.com/news/asco-a…
Excited to share our upcoming poster presentation at #ASCO24 @ASCO
where we will present a confirmed complete response in a patient with Anaplastic #Thyroid Cancer with our autologous CAR T therapy AIC100.
businesswire.com/news/home/2…
As of the data cutoff date, 10 patients (6 ATC; 4 PDTC) were infused with AIC100 at 3 dose levels (DLs). No dose-limiting toxicities were observed across all dose levels, and the maximum tolerated dose was not reached.
41
Excited to announce our presentation at @ASCO 2024 about our affinity-tuned CAR T therapy AIC100. #ASCO24
Read the full release:
businesswire.com/news/home/2…
1
106
AffyImmune Therapeutics retweeted
I'm very pleased to serve on the Clinical and Regulatory Advisory Board of @affyimmune - Hagop Youssoufian
#Cancer #Career #CARTTherapies #LungCancer #OncoDaily #Oncology #ThyroidCancer #Biotechnology
oncodaily.com/47136.html
AffyImmune Presents Preclinical Data on AIC100 Affinity-Tuned CAR T Targeting ICAM-1 in Additional Solid Tumor Types at #AACR24 @AACR
businesswire.com/news/home/2…
Excited to announce the formation of our Clinical and Regulatory Advisory Board today:
businesswire.com/news/home/2…
39










